Nxera Pharma Statistics
Total Valuation
Nxera Pharma has a market cap or net worth of JPY 108.06 billion. The enterprise value is 128.60 billion.
Market Cap | 108.06B |
Enterprise Value | 128.60B |
Important Dates
The last earnings date was Friday, November 1, 2024.
Earnings Date | Nov 1, 2024 |
Ex-Dividend Date | n/a |
Share Statistics
Nxera Pharma has 89.90 million shares outstanding. The number of shares has increased by 7.43% in one year.
Current Share Class | n/a |
Shares Outstanding | 89.90M |
Shares Change (YoY) | +7.43% |
Shares Change (QoQ) | +0.25% |
Owned by Insiders (%) | 8.28% |
Owned by Institutions (%) | 23.99% |
Float | 66.02M |
Valuation Ratios
PE Ratio | n/a |
Forward PE | 39.85 |
PS Ratio | 3.62 |
PB Ratio | 1.59 |
P/TBV Ratio | n/a |
P/FCF Ratio | 62.03 |
P/OCF Ratio | n/a |
PEG Ratio | n/a |
Enterprise Valuation
The stock's EV/EBITDA ratio is 48.38, with an EV/FCF ratio of 73.82.
EV / Earnings | -34.65 |
EV / Sales | 4.39 |
EV / EBITDA | 48.38 |
EV / EBIT | n/a |
EV / FCF | 73.82 |
Financial Position
The company has a current ratio of 4.01, with a Debt / Equity ratio of 1.02.
Current Ratio | 4.01 |
Quick Ratio | 3.73 |
Debt / Equity | 1.02 |
Debt / EBITDA | 26.11 |
Debt / FCF | 39.84 |
Interest Coverage | -0.59 |
Financial Efficiency
Return on equity (ROE) is -5.90% and return on invested capital (ROIC) is -0.61%.
Return on Equity (ROE) | -5.90% |
Return on Assets (ROA) | -0.54% |
Return on Capital (ROIC) | -0.61% |
Revenue Per Employee | 78.70M |
Profits Per Employee | -9.98M |
Employee Count | 350 |
Asset Turnover | 0.19 |
Inventory Turnover | 1.93 |
Taxes
Income Tax | n/a |
Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -20.51% in the last 52 weeks.
Beta (5Y) | n/a |
52-Week Price Change | -20.51% |
50-Day Moving Average | 1,263.00 |
200-Day Moving Average | 1,467.93 |
Relative Strength Index (RSI) | 45.62 |
Average Volume (20 Days) | 647,770 |
Short Selling Information
Short Interest | n/a |
Short Previous Month | n/a |
Short % of Shares Out | n/a |
Short % of Float | n/a |
Short Ratio (days to cover) | n/a |
Income Statement
In the last 12 months, Nxera Pharma had revenue of JPY 29.28 billion and -3.71 billion in losses. Loss per share was -42.09.
Revenue | 29.28B |
Gross Profit | 23.85B |
Operating Income | -1.31B |
Pretax Income | -5.11B |
Net Income | -3.71B |
EBITDA | 2.66B |
EBIT | -1.31B |
Loss Per Share | -42.09 |
Balance Sheet
The company has 48.87 billion in cash and 69.41 billion in debt, giving a net cash position of -20.54 billion or -228.48 per share.
Cash & Cash Equivalents | 48.87B |
Total Debt | 69.41B |
Net Cash | -20.54B |
Net Cash Per Share | -228.48 |
Equity (Book Value) | 67.76B |
Book Value Per Share | 753.72 |
Working Capital | 44.92B |
Cash Flow
In the last 12 months, operating cash flow was 2.43 billion and capital expenditures -683.00 million, giving a free cash flow of 1.74 billion.
Operating Cash Flow | 2.43B |
Capital Expenditures | -683.00M |
Free Cash Flow | 1.74B |
FCF Per Share | 19.38 |
Margins
Gross margin is 81.46%, with operating and profit margins of -4.46% and -12.68%.
Gross Margin | 81.46% |
Operating Margin | -4.46% |
Pretax Margin | -17.45% |
Profit Margin | -12.68% |
EBITDA Margin | 9.08% |
EBIT Margin | -4.46% |
FCF Margin | 5.95% |
Dividends & Yields
Nxera Pharma does not appear to pay any dividends at this time.
Dividend Per Share | n/a |
Dividend Yield | n/a |
Dividend Growth (YoY) | n/a |
Years of Dividend Growth | n/a |
Payout Ratio | n/a |
Buyback Yield | -7.43% |
Shareholder Yield | -7.43% |
Earnings Yield | -3.50% |
FCF Yield | 1.61% |
Stock Splits
The last stock split was on June 27, 2018. It was a forward split with a ratio of 4.
Last Split Date | Jun 27, 2018 |
Split Type | Forward |
Split Ratio | 4 |
Scores
Nxera Pharma has an Altman Z-Score of 1.27. A Z-score under 3 suggests an increased risk of bankruptcy.
Altman Z-Score | 1.27 |
Piotroski F-Score | n/a |